In mRCC, Targeted Therapies Show Activity Following PD-1/PD-L1 Blockade

Both vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors and mammalian target of rapamycin (mTOR) inhibitors demonstrate antitumor activity following programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade in patients with metastatic renal cell carcinoma (mRCC), a new study published online ahead of print in the European Journal of Cancer has shown.¹

Results showed that median time to treatment failure on subsequent targeted therapy was 6.6 months and 1-year and 2-year overall survival from the initiation of subsequent targeted therapy was 58% (95% CI: 41-72) and 36% (95% CI: 18-54), respectively.

For the study, researchers sought to evaluate the efficacy of targeted therapy after PD-1/PD-L1 blockade in patients with mRCC.

The medical records of 99 patients who were treated with investigational PD-1 or PD-L1 pathway immunotherapy were analyzed to assess median time to treatment failure and overall survival after initiation of subsequent targeted therapy.

Of those 99, 56 patients received subsequent targeted therapy, 44 of which received VEGF/VEGFR inhibitors and 12 received mTOR inhibitors. Targeted therapy was administered as second-line, third-line, or beyond third-line in 16%, 43%, and 41% of patients who had received PD-1/PD-L1 monoclonal antibodies.

Reference

1. Albiges L, Fay AP, Xie W, et al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma [published online ahead of print September 5, 2015]. Eur J Cancer. doi: 10.1016/j.ejca.2015.08.017.